- Your selection
- Clear all
- Pharmaceuticals x
- English x
- Global x
- Marketing x
4 case(s) found.
Lucentis, a forthcoming breakthrough drug against wet age-related macular degeneration (AMD), will be marketed by Genentech in the U.S. and Novartis in other countries.
Reference 5718
Published 27 Jan 2014
Length 22 page(s)
Topic Marketing
Region Global
Industry Pharmaceuticals, Medical Devices
Lucentis, a forthcoming breakthrough drug against wet age-related macular degeneration (AMD), will be marketed by Genentech in the U.S. and Novartis in other countries.
With 2005 sales of $12.2 billion, Lipitor was the world's largest pharmaceutical product and, by itself, would have been the 14th largest pharmaceutical company. The (A) case describes the market entry and rise to market leadership of Lipitor.
Reference 5404
Published 10 Jan 2006
Length 25 page(s)
Topic Marketing
Region Global
Industry Pharmaceuticals
With 2005 sales of $12.2 billion, Lipitor was the world's largest pharmaceutical product and, by itself, would have been the 14th largest pharmaceutical company. The (A) case describes the market entry and rise to market leadership of Lipitor.
With 2005 sales of $12.2 billion, Lipitor was the world's largest pharmaceutical product and, by itself, would have been the 14th largest pharmaceutical company. The (A) case describes the market entry and rise to market leadership of Lipitor.
Reference 5404
Published 01 Oct 2006
Length 7 page(s)
Topic Marketing
Region Global
Industry Pharmaceuticals
With 2005 sales of $12.2 billion, Lipitor was the world's largest pharmaceutical product and, by itself, would have been the 14th largest pharmaceutical company. The (A) case describes the market entry and rise to market leadership of Lipitor.
Initially available only in low doses, sales of the aggressively priced Baycol/Lipobay anti-cholesterol drug pick up when the product is marketed at higher doses, especially in the large US market. On course for 1 billion sales, the product is withdrawn worldwide in response to reports of a number of deaths associated with its use.
Reference 5385
Published 07 Jan 2006
Length 24 page(s)
Topic Marketing
Region Global
Industry Pharmaceuticals
Initially available only in low doses, sales of the aggressively priced Baycol/Lipobay anti-cholesterol drug pick up when the product is marketed at higher doses, especially in the large US market. On course for 1 billion sales, the product is withdrawn worldwide in response to reports of a number of deaths associated with its use.